FDA

/Tag:FDA

The Grey Market Is…

  Keith Watts Abstract This is the first in a series discussing the unnecessary failure of major drug manufacturers to address legitimate patient-specific early access, also called “named patient” access, worldwide. US pharmaceutical manufacturers have a poor understanding of the gray market that channel supplying newly FDA approved medicines outside the US. This poor understanding [...]

By | 2017-12-06T16:52:50+00:00 December 6th, 2017|News|0 Comments